Get started

Stockclass

The Big Exit | How One Auditor Walked Away from Super MicroThe Governance Shortfall: Inside Super Micro’s Auditor Crisis On Wednesday, shares of the high performance server and storage solutions provider faced renewed selling pressure after the unexpected resignation of its audit firm, Ernst & Young LLP(EY) In July 2024, EY alerted the Audit Committee about several concerns related to governance, transparency, internal controls, and the risk of delayed filing of the company's annual report. In response, the Board formed an independent Special Committee to investigate these matters, engaging Cooley LLP and forensic accounting firm Secretariat Advisors, LLC. Although EY and the Board received preliminary updates on the investigation, the final conclusions have not yet been shared. The ongoing review raised doubts for EY regarding the company’s adherence to the COSO Framework principles for internal controls. EY questioned the company’s commitment to integrity, the independence of the Audit Committee, and the reliability of management’s and the Audit Committee's representations. In its resignation letter, EY expressed its inability to rely on these representations or be associated with the company's financial statements, citing legal and professional obligations. Despite the developments, Super Micro has indicated no expected changes to previously issued financial statements. The company plans to provide a Q1/FY2025 business update next week. However, it’s surprising that management didn’t include preliminary Q1 results in Wednesday's announcement, which could have mitigated the negative impact on its stock. Super Micro is nearing a Nasdaq deadline to either regain compliance with listing requirements or submit a plan. With the auditor’s unexpected departure, it may be difficult for the company to present a viable plan, raising the risk of a near-term delisting. This resignation comes at a critical time for Super Micro, as its rapid growth requires substantial working capital. Based on management’s projections, FY2025 cash needs could reach up to $3 billion, likely necessitating additional capital early next year. However, raising funds without audited financials could be challenging, potentially forcing Super Micro to relinquish market share to competitors like Dell Technologies or Hewlett Packard Enterprise. In my view, EY’s departure increases the likelihood of a prolonged accounting review, which could hinder Super Micro’s ability to secure funding for anticipated growth. Therefore, it is crucial for the company to report strong preliminary Q1/FY2025 results and present a positive outlook next week. Super Micro Computer’s troubles continue, as its auditor resigned due to concerns over management’s integrity and the Audit Committee's independence. This situation makes it unlikely for the company to achieve compliance with Nasdaq requirements soon, raising the potential for a near-term delisting. With a need to re-enter the capital markets in early 2025, audited financials remain essential. A failure to secure funding could result in significant market share loss to major competitors like Dell Technologies and Hewlett Packard Enterprise. Given these challenges, the increased risk of prolonged financial review, and a likely near-term delisting, I am reaffirming my "Sell" rating on Super Micro Computer's common shares.
NASDAQ:SMCIShort
by moonypto
2
Airbnb | ABNB Airbnb is the leader in Alternative Accommodations and experiences. I believe their community of individual hosts and strong brand differentiates them from travel peers. The emerging trend of long-term stays would boost Airbnb’s profit margins and expand the entire travel accommodation market size Airbnb estimates its current total addressable market to be $3.4 trillion, including $1.8 trillion in short term stays, $ 210 billion in long term stays, and $ 1.4 trillion in experiences. Coupled with a notably underpenetrated market size, the global travel market is growing at an above GDP rate. Airbnb’s current market penetration represents less than 2% of the share. As such, there is a huge runway for Airbnb’s growth over the next decade. In terms of competition, most Online Travel Agencies (OTA) provide traditional hotel accommodation (Marriott, Hilton, Accor, Wyndham, and InterContinental, for example). These OTAs are not the real competitors for Airbnb. Instead, Booking.com (BKNG) is expanding its traditional hotel business into the alternative accommodation industry. Expedia (EXPE) entered the alternative accommodation market via the acquisition of VRBO in December 2015. However, Airbnb has the first-mover advantage with a very strong brand. I believe Airbnb’s technology and supplies are superior to their peers, and it is hard for Expedia and Booking.com to compete against Airbnb in the alternative accommodations space. One of the main expenses for Online Travel Agencies is sales and marketing. They have to spend billions of dollars on Google, Facebook, and other social media platforms to attract traffic. The table below shows the sales and marketing expenses as a percentage of sales. Both Booking.com and Expedia spend almost half of their sales on sales and marketing. According to Airbnb’s disclosure, 80% of their website traffic comes from direct and organic search. In contrast, Booking.com and Expedia only have 60% direct traffic. In other words, Airbnb has the highest brand awareness among these travelers. With a high ratio of direct traffic and organic search, Airbnb spends much less than its peers. In Q1 FY23’s earning call, Airbnb indicated their sales and marketing expense as percentage of sales would remain the same in FY23. In late 2019, Airbnb's costs were rising, and growth was slowing. They spent a huge amount of money on performance marketing, which was basically selling their products as a commodity. Their product was looking less different from their competitors. When the COVID occurred, they lost 80% of sales in eight weeks, and they shut down all marketing spending. Interestingly, when the travel market rebounded, Airbnb's business came back to almost the same level as before, with much less marketing expenses. Currently, they spend much less on performance marketing, and most of their expenses are focused on their products/services. They have had 600,000 articles about Airbnb. These efforts have put Airbnb in a much better shape today. 90% of Airbnb's hosts are individuals. Airbnb can capitalize on the personal experience provided by these unique individual hosts, as opposed to a standard hotel service. Customers can find unique properties, differentiated amenities, as well as local insights from these individual hosts. Airbnb is putting in a lot of effort into the experience market. In Q4 FY22's earnings call, Airbnb expressed that they were beginning to ramp up their Airbnb Experience business and expect to launch more products/services over the coming years. In my opinion, Airbnb Experience may not bring notable direct sales to Airbnb, but it would enhance the stickiness and loyalty of Airbnb's customers. Airbnb Experience would make the Airbnb platform unique and boost their sales indirectly. Furthermore, Airbnb Experience could become more relevant with AI technology. In Q1 FY23's earnings call, Airbnb disclosed that they are building AI into their products. Airbnb is working with OpenAI ChatGPT, and Airbnb will embed ChatGPT into their app. The AI powered product will be launched next year. Leveraging AI technology, Airbnb can make their Airbnb Experience and accommodation recommendations more relevant to any consumer. To put it another way, Airbnb would know your preferences for travel destinations and accommodations before you start searching for anything. Long-term Stay: As disclosed, 20% of Airbnb's gross bookings are long-term stays currently. Long-term stays are the fastest-growing segment in terms of trip length. The pandemic also accelerated some inevitable growth for long-term stays. Long-term stays mean higher margins for both hosts and Airbnb. In Q1 FY23's earnings call, Airbnb indicated that long-term stays would be one of the biggest growth areas over the next five years. Airbnb made over a dozen upgrades to long-term stays based on affordability, and they also have new discounting tools for hosts on weekly and monthly stays. Airbnb expects more hosts to exclusively list long-term stays with Airbnb. In addition, 62% of Airbnb's guests are under 34 years old, and Airbnb is focusing on the next generation of travelers. These young customers are more likely to use Airbnb as the platform for long-term stays. The key thing to remember is that more long-term stays mean higher margins for Airbnb. Airbnb indicated that, in the current macroeconomic environment, consumers are looking for affordable ways to travel on Airbnb. Airbnb is adding more affordable accommodations to their platform. The average price of Airbnb rooms is only $67 per night. Before the pandemic, 80% of Airbnb's sales were coming from either cross-border or urban accommodations. The cross-border business would contribute more sales to Airbnb than other types of travel. The cross-border traveling could be very weak if high inflation persists. Despite this, the global travel market had been growing fast in the past, and I expect the growth will continue in the future. We are using a two-stage DCF model to estimate Airbnb’s fair value. In the model, we assume 20% of normalized sales growth rate, which we believe is quite conservative. We assume they can expand their operating margin by 30bps annually and will reach 25.5% in FY32.Their free cash flow conversion was quite healthy in the past, and we assume they will deliver 35.8% in FY32. In addition, we use 10% of WACC, and 15% of nonGAAP tax rate in the model. The present value of Free Cash Flow to the Firm (FCFF) over the next 10 years is estimated to be $32 billion, and the present value of terminal value is $88 billion. As such, the total enterprise value is estimated to be $120 billion. Adjusting gross debt and cash balance, the fair value of the stock price is $ 200, according to our estimate. All things considered, the huge underpenetrated market, strong brand awareness, and growing trend of long-term stays, in my opinion, will provide Airbnb with a huge runway for growth over the next decade. Their competitors are way behind them, and Airbnb would be the best player for the alternative accommodation service provider. In my view, the current stock price is significantly undervalued, and we encourage investors to buy during the weakness. at the end I always bet on Brian Chesky
NASDAQ:ABNBLong
by moonypto
2
Shopify Inc | SHOP & AIShopify stock has seen sideways momentum for the last few weeks despite posting good results in the recent quarter. One of the reasons is the bull run in early 2023 due to which the stock has seen over 60% jump in year-to-date. Shopify has been able to reignite revenue growth in the last few quarters and there are strong tailwinds that can help the company improve its topline. At the same time, Shopify has been able to improve the conversion of Gross Merchandise Value or GMV into revenue due to better services. Shopify’s GMV has increased 11x between the last quarter of 2016 and the last quarter of 2022. During this time, Shopify’s quarterly revenue base has increased from $130 million to $1.7 billion or 13x. Shopify’s GMV for 2022 was $195 billion and rapid growth in this key metric should help the company improve monetization. The company has also undertaken some cost-cutting which is having a positive impact on the bottom line. Analysts have forecasted Shopify’s EPS at $1 for fiscal 2025 which means that the stock is trading 60 times the EPS estimate of 2025. However, better monetization and focus on cost optimization could help the company deliver good EPS growth in the next few quarters. The PS ratio is also at 12 which is significantly lower than the pre-pandemic years. Shopify stock can deliver good returns in the long term as the company adds new services and improves its GMV growth trajectory. Shopify reported a GMV of $5.5 billion in December 2016 quarter. This has increased to $60 billion in the recent December 2022 quarter. Hence, Shopify’s GMV has increased to 11 times within the last seven years. On the other hand, Shopify’s revenue during the December quarter has increased by 13 times, from $130 million to $1.7 billion. This growth trend shows that the company is able to convert more GMV into actual revenue. One of the main reasons behind this trend is that Shopify is adding new services and it can charge customers a higher commission for these services. Shopify’s GMV for 2022 was a staggering $195 billion. The company has been able to reignite revenue growth in the last few quarters. The YoY revenue growth hit a bottom of 15% in June 2022. Since then the YoY revenue growth has picked up again as the company faces easier comps. In the recent quarter, the company reported YoY revenue growth of over 30% which is quite high when we consider that the GMV base of Shopify is more than $200 billion. The revenue growth will not build a bullish momentum for the stock unless the company can deliver sustainable profitability. During the pandemic years, Shopify’s revenue growth and high EPS helped the stock reach its peak. The company would need to focus on profitability in the next few quarters in order to rebuild a long-term bullish rally. Shopify has divested from its logistics business which should help improve the bottom line. We should also see better monetization of current services as the company tries to build new AI tools. The EPS estimates for 2 fiscal years ahead have steadily improved in the last few quarters. According to current consensus, Shopify should be able to deliver EPS of $1 in fiscal year 2025. However, it is highly likely that Shopify will beat these estimates as the company launches new initiatives to improve monetization of its massive GMV base. Shopify’s trailing twelve months EPS during the peak of the pandemic went to $2.6. If the company can get close to this EPS rate by 2025, we should see a significant bullish run in the stock. The recent cost-cutting should also help the company improve the bottom line. We have seen a similar trend in all the Big Tech companies who have reported a rapid growth in EPS as their headcount was reduced. While most analysts agree over the long-term revenue growth potential of Shopify, some of them are wary of the pricey valuation of the stock. Shopify is trading at 12 times its PS ratio. This is quite high when we compare with most of the other tech players and even Shopify’s peer like Wix (WIX), Etsy (ETSY), and others. However, it should be noted that Shopify’s PS ratio is significantly lower than the average PS multiple prior to the pandemic when the stock had an average PS ratio of over 20. Shopify’s revenue estimates for 2 fiscal years ahead is close to $10 billion which is equal to annualized revenue growth of over 25%. If we look at this metric, Shopify stock is trading at 7 times the revenue estimate of fiscal year 2025. This looks reasonable if the company can also manage to improve its EPS trend over the next few years. The long-term tailwind from ecommerce growth is still very strong. Shopify will benefit from an increase in GMV and a higher ecommerce market share in key markets. This should help the company gain pricing leverage over other competitors and also improve its monetization momentum Shopify has reported a faster revenue growth rate compared to its GMV growth in the last few years. This shows that the company is able to charge higher rate for additional services. There has been an acceleration in revenue growth over the last few quarters. Shopify has also divested from logistics services which were pulling down the profitability of the company. Shopify could deliver over 20% YoY revenue growth for the next few years as the company gains from strong tailwinds within the ecommerce business. If Shopify regains its earlier ttm EPS of $2 by 2025, we could see a strong bull run within the stock. While the stock is not cheap, it seems to be reasonably valued and longer-term investors could gain a better return from Shopify, making the stock a Buy at current price.
NYSE:SHOPLong
by moonypto
2
Nvidia Stock Soars On Blowout GuidanceSoaring demand for the chips needed to train the latest wave of generative artificial intelligence systems such as ChatGPT led Nvidia to issue a revenue forecast far ahead of Wall Street expectations, prompting a surge in its stock price in after market trading. The US chipmaker on Wednesday said it expected sales to reach 11bn dollar in the three months to the end of July, more than 50 per cent ahead of the 7.2bn dollar analysts had been expecting and confirming its position as the biggest short-term beneficiary of the AI race that has broken out in the technology industry. The forecast fuelled a 27 per cent leap in Nvidia’s shares, which had already more than doubled since the start of the year, and lifted its stock market value to a record 960 bn dollar. Jensen Huang, chief executive, said the company was “significantly increasing our supply to meet surging demand” for its entire family of data centre chips, including the H100, a product launched this year that was designed to handle the demands of so-called large language models such as OpenAI’s GPT4. The race in the tech industry to develop larger AI models has led some customers to worry privately about a shortage of H100 chips, which only went on sale earlier this year. However, Nvidia’s $4.28bn in sales to data centre customers in its latest quarter topped even the most optimistic analysts’ forecasts, and the company said there had been strong sales of both the H100 and its A100 chips, based on its previous chip architecture. Nvidia’s forecast noted a potential doubling of sales to data centre customers in three months, even though data centre sales were running at an annualised rate of $17bn in the opening quarter of this year. Growth is coming from customers across the board, Kress said, with consumer internet companies, cloud computing providers and enterprise customers all rushing to apply the generative AI to their businesses. The bullish forecast came as Nvidia reported revenue and earnings in its latest quarter, to the end of April, had also topped forecasts, thanks to a jump in sales to data centre customers as demand for AI took off. Revenue reached $7.19bn, up 19 per cent from the preceding three months but down 13 per cent from the year before, as sales of chips for gaming systems dropped. Earnings per share rose 22 per cent from a year before to 82 cents, or $1.09 on the pro forma basis Wall Street judges the company. The consensus view on Wall Street had been for revenue of $6.52bn and pro forma earnings of 92 cents a share. now let's delve into the numbers. Nvidia's different business units did not all perform equally well during the quarter - which can be expected, of course. Nvidia's data center business grossed revenues of $4.3 billion during the first quarter, which represents a new record high. Data center demand is not very cyclical, and companies kept investing in new equipment despite a potential recession being on the horizon. This can be explained by the fact that data centers are mission critical for many companies, so they don't really have a lot of choice when it comes to allocating capital to this space. Strong data center sales also have been seen in the results of other chip companies such as Advanced Micro Devices (AMD). Both Nvidia and AMD also were able to benefit from the weak performance of their competitor Intel (INTC), as Intel has been losing market share in the data center space in recent quarters due to self-inflicted problems and an unconvincing product line-up. Nvidia is a major graphic chip or GPU player and is thus heavily impacted by the performance of related end markets. This includes both cryptocurrency mining and gaming. While some cryptocurrencies can't be mined with GPUs economically, such as Bitcoin, others, such as Ethereum, can be mined with GPUs. Ethereum moved from a proof-of-work model to a proof-of-stake model in the fall of 2022, but some miners still use GPUs for Ethereum mining. Not surprisingly, Nvidia's sales to this end market depend on the price for cryptocurrencies - when cryptocurrencies are expensive, miners are more eager to acquire additional GPUs and they may also be willing to pay high prices for them. During times when cryptocurrencies are less expensive, mining is less profitable, and GPU demand from cryptocurrency miners wanes. This has had an impact on Nvidia's sales in the past and likely played a role in Nvidia's Q1 sales as well. GPU sales have been under pressure in recent quarters due to lower demand by gamers as well. Many that like to play video games upgraded their hardware during the lockdown phase of the pandemic when staying at home meant that consumers had more time for video games. With many gamers having relatively new equipment, demand has declined in the recent past. At the same time, inflation pressures consumers' ability to spend on discretionary goods. On top of that, some consumers prefer to spend their money on experiences over things now as there are no lockdowns or travel restrictions in place any longer. All in all, this has resulted in a difficult macro environment for Nvidia's gaming business. Combined, the headwinds for the gaming market and the cryptocurrency market explain why Nvidia's sales and profits kept declining during the most recent quarter, relative to the results the company was able to generate one year earlier. The strong performance in the data center space was not enough to offset the headwinds Nvidia experienced in other areas. I personally going to take huge profit right now and wait for 250 $ levels
NASDAQ:NVDA
by moonypto
5
How To Pick Top Pharma Stocks like a ProAnalyzing the pharmaceutical industry, whose products play a key role in improving the quality of life of people around the world, is quite challenging sometimes also it requires deep knowledge and a careful approach, as I believe that investors should consider many factors, starting with evaluating the efficacy of the analyzed company's medications, including in relation to its competitors and the "gold standards," and ending with an analysis of its financial indicators In this article you will learn how to pick Top Pharma stocks like a pro trader and which factors you should consider, so buckle up 1/ Recognizing the risks At the very beginning, an investor you must recognize that the pharmaceutical industry is highly competitive, where a company's investment attractiveness depends not only on the rate of expansion of its portfolio of product candidates, revenue growth, margins, the amount of total debt and cash on the balance sheet but is also heavily influenced by the expiration of patents on medications and vaccines. Moreover, in recent months, the healthcare sector has increasingly felt the impact of the upcoming 2024 US presidential elections, as some politicians are aiming to further tighten regulation of drug prices despite the existing Inflation Reduction Act. 2/ Leveraging data to your advantage The second step use data wisely, you should check all kinda data including stock screener, transcripts of earnings calls, financial results for the last quarters, analyst expectations, options data... The goal is to filter companies in poor financial condition, as well as those that trade at a significant premium to the sector and/or competitors I would also like to point out that in the current market environment, with Fed interest rates remaining at multi year highs, I do not recommend investing in companies with market caps below $500 million, as they typically have limited cash reserves and weaker institutional backing Also, I'd recommend investors read 10-Ks and 10-Qs, especially the section related to debt and sources of financing of the company's operations, to reduce the likelihood of an "unexpected" drop in the share price. A striking example is Invitae Corporation aka NVTAQ which declared bankruptcy in mid February 2024! Was there a prerequisite for this? The answer is yes since the company continued to generate negative cash flow and also had convertible senior notes maturing in 2028. Convertible notes can involve significant financial risks if the company cannot effectively use the cash to grow the business and break even. In this case, management will not be able to pay off the bonds with cash reserves and will have to resort to significant dilution of investors. In my opinion, Pacific Biosciences of California, Inc. NASDAQ:PACB may face this problem because it has convertible senior notes maturing in 2028 and 2030. Factors that concern me include the company's declining revenue and total cash and short-term investments in recent quarters, while its operating expenses remain extremely high at around $80 million per quarter. Let's return to the second step in my approach to selecting the most promising assets in the healthcare sector. When selecting companies with market caps between $4 billion and $40 billion, I use more parameters since most of them already have FDA approved drugs and/or vaccines. As a result, it is also necessary to consider the rate of growth of operating income, net debt/EBITDA ratio, and how management copes with increased marketing and production costs. Finally, let's move on to the last basket, which contains pharmaceutical companies with market capitalizations exceeding $40 billion. I think, this group is best suited for more conservative investors looking for assets offering attractive dividend yields and growing net income, supported by a rich portfolio of FDA approved and experimental drugs. So, from Big Pharma, I like Pfizer Inc NYSE:PFE , AbbVie Inc NYSE:ABBV , Merck & Co NYSE:MRK and AstraZeneca PLC NASDAQ:AZN . I also want to include Novartis AG NYSE:NVS and Roche Holding AG OTC:RHHBY in this group sometimes investors need to make exceptions, namely if one larger company buys out a smaller player and/or when a major partnership agreement is concluded, as was the case between Merck and Daiichi Sankyo Company, Limited OTC:DSKYF in 2023. Also, in the event of a major acquisition or merger, the company's debt may temporarily increase sharply. If its management has previously implemented effective R&D and financial policies, the "net debt/EBITDA ratio" A remarkable example of a company falling into the "value trap" is Takeda Pharmaceutical Company Limited NYSE:TAK , which overpaid for Shire. This deal did not significantly strengthen or rejuvenate the Japanese company's portfolio of drugs. As a result, it had to sell off billions of dollars in assets to pay off its debt partially. However, despite all the efforts of Takeda's management, its net debt/EBITDA ratio, although it fell below 5x, remains high, namely about 4.7x at the end of March 2024. 3/ Identifying promising therapeutic areas In general, the more prevalent a disease is, the larger the total addressable market for a drug and, as a result, the higher the chances that it will become a commercially successful product. Global spending on cancer medications will reach $377 billion by 2027, followed by immunology, and diabetes will come in third with an estimated spending of about $169 billion What challenges arise when choosing pharmaceutical companies? you should also keep in mind that the larger the market, the higher the competition between medicines, as companies strive to grab as big a piece of the pie as possible. As a result, for drug sales to take off, they need to have significant competitive advantages over the "gold standard." These competitive advantages may include greater efficacy in treating a particular disease, less frequent administration, a more favorable safety profile, and a more convenient route of administration. So, in recent years, competition in the global spinal muscular atrophy treatment market has intensified. Spinal muscular atrophy is a genetic condition. Currently, three drugs have been approved to combat the disorder, including Biogen Inc.'s (BIIB) Spinraza, Roche/PTC Therapeutics, Inc.'s (PTCT) Evrysdi, and Novartis AG's (NVS) gene therapy Zolgensma. All three products have similar efficacy, but Evrysdi has a more favorable safety profile and is the more convenient route of administration, namely the oral route, which is reflected in its sales growth rate from year to year. The second pitfall is the company's pipeline of experimental drugs. I believe that financial market participants opening an investor presentation that presents a company's pipeline, especially if its market cap is below $5 billion, should also pay close attention to what stage of clinical trial activity its experimental drugs are in. if a pharmaceutical company has most of its product candidates in the early stages of development, this represents a significant risk because, in this case, institutional and retail investors are often overly optimistic about the prospects for the drugs' mechanisms of action and/or clinical data obtained in a small group of patients. Simultaneously, as is often the case, the higher the optimism, the less favorable the risk/reward profile. In most cases, the larger and more diverse the patient population, the weaker the efficacy of a drug relative to what was seen in Phase 1/2 clinical trials. This ultimately leads to a downward valuation of its likelihood of approval and casts doubt on its ability to take significant market share from approved medications. This may subsequently reduce the company's investment attractiveness, making it more difficult to attract financing for its operating activities. As a result, I recommend excluding any company that, instead of focusing its financial resources on the most promising product candidates, conducts multiple early-stage clinical trials to evaluate the efficacy of its experimental drugs. In my experience, the most successful pharmaceutical companies focus their efforts on bringing up to three product candidates to market and then reinvesting the revenue from their commercialization into developing the rest of the pipeline. The table below highlights the following parameters that I use to screen out the least promising companies. A third factor that investors, especially those new to the investment world, should consider is that large pharmaceutical companies are leaders in certain therapeutic areas, with a rich portfolio of patents covering various mechanisms of action and delivery methods of drugs, making it more difficult and more prolonged for smaller players to find product candidates that could potentially have the competitive advantages. So, Novo Nordisk A/S NYSE:NVO and Eli Lilly and Company NYSE:LLY have long been leaders in the global diabetes and weight loss drugs markets, and only very recently, they may be joined by Amgen Inc. NASDAQ:AMGN , Roche Holding, and several other companies 4/ Assessing a company's drug portfolio in comparison to competitors Evaluating the effectiveness, safety profile, and mechanism of action of a medication, as well as comparing clinical data with its competitors, takes a lot of time and effort. I provided examples of drugs and the most promising mechanisms of action in the obesity treatment market. Their manufacturers are Eli Lilly, Novo Nordisk, Roche Holding, Viking Therapeutics, Inc, Amgen, Pfizer, Altimmune, Inc, OPKO Health, Inc, Boehringer Ingelheim, and Zealand Pharma A/S 5/ When market exclusivity for a company's key medications ends Every financial market participant who is considering investing in pharmaceutical companies should consider the expiration time of key patents of medicines. Marketing exclusivity represents protection against the entry of a generic version and/or biosimilar of a branded drug into the market, thereby allowing the company to recoup the resources spent on its development and, in the event of its commercial success, also reinvest the money received to accelerate the development of the remaining product candidates. Where can you find information about patent expiration dates? All the necessary information is either in 20-Fs/10-Ks or on the FDA website, namely in the "Orange Book" section. let's take Eli Lilly as an example. Open the latest 10-K. Then, the CTRL + F combination opens the ability to find specific words in the document. I usually enter "Expiry Date" or "compound patent" to find the patent section.nvestors can also find information about patents on the FDA website. As an example, I enter "Mounjaro" in the top line, and a list of patents opens that protect Eli Lilly's blockbuster from the introduction of its generic versions onto the market.hen, clicking on "Appl. No." will open information about the submission date of the patent and when it will expire. 6/ Evaluating the impact of insider share transactions The next step in selecting the most interesting assets in the healthcare sector is to analyze Form-4s. The CEO, CFO, and other key members of the company's management buy or sell shares from time to time.I am only interested in analyzing purchases since, most often, sales by management are option exercises carried out to pay taxes. When management starts making large outright purchases of a company's shares, it can signal that it believes in its long-term growth potential.if more than two top managers buy a large block of shares within two weeks of each other, it significantly increases the likelihood of the company's stock price rising in the next two months from the moment of their transactions But as with everything, there are exceptions, such as in the case of OPKO Health, which is developing a long-acting oxyntomodulin analog for the treatment of obesity together with LeaderMed Group.Over the past 12 months, OPKO's management, especially CEO Phillip Frost, has purchased over 12 million shares. However, despite this, its stock price has fallen by 27% over the same period. I believe that the key reasons for the divergence between these two facts are investors' lack of confidence in Phillip Frost's ability to make the company profitable again, as well as its low cash reserves. Therefore, companies like OPKO Health have already been eliminated at the second step of selection using Seeking Alpha's screener. 7/ CEO Performance in Business Development The CEO plays a crucial role in the success of a pharmaceutical company since the pharmaceutical industry is highly dynamic, and the competition between Big Pharma is especially high, I advise readers to pay attention to the track record of the CEO, especially how he copes with force majeure situations, as well as how effective the R&D policy is carried out under his leadership. 8/ Identifying Entry and Exit Points for Long-Term Investments The eighth step is in addition to the information that was obtained in the previous steps, as well as the analysis of financial risks and various financial metrics of the company, including its net debt, maturity dates of bonds, historical revenue growth rates, EBIT, gross margin, I build a DCF model with the ultimate goal of determining the price target. it is necessary to conduct a technical analysis of them, as well as the main ETFs that include them. In my opinion, the key ETFs are the SPDR® S&P Biotech ETF AMEX:XBI , Fidelity Blue Chip Growth ETF AMEX:FBCG , iShares Biotechnology ETF NASDAQ:IBB , and VanEck Pharmaceutical ETF $PPH. The purpose of technical analysis is to determine the stop-loss level and entry points at which the risk/reward profile is most favorable. taking profit is not that easy cuz you must master your emotions and greed which damn hard 9/ Creating a Watchlist Based on Risk/Reward Ratio The purpose of which is to create a watchlist of the companies I have selected based on the previous steps. I make several lists of companies based on their market caps and also rank them according to risk/reward profile, that is, in the first place is the stock that I think has minimal risks and at the same time can bring the greatest potential profit. I also advise creating small notes on each company, which can include information about risks, support/resistance zones, dates of publication of clinical data, and any thoughts you have that will make your decision more conscious when opening a position “What’s your secret sauce for choosing pharma stocks?”
NYSE:NVOEducation
by moonypto